期刊
JOURNAL OF CARDIOVASCULAR TRANSLATIONAL RESEARCH
卷 9, 期 1, 页码 80-84出版社
SPRINGER
DOI: 10.1007/s12265-015-9671-z
关键词
Biomarker; Diagnosis; Dilated cardiomyopathy; Endothelial progenitor cell; Flow cytometry; Heart failure
资金
- Ministerio de Educacion y Ciencia [SAF2014-59892, SAF2014-59892-R]
- Fundacio La MARATO de TV3 [122232, 201502-30, 201516-10]
- Fundacio Daniel Bravo Andreu
- Sociedad Espanola de Cardiologia
- Societat Catalana de Cardiologia
- Generalitat de Catalunya (SGR)
- Academia de Ciencies Mediques i de la Salut de Catalunya i de Balears
- Red de Terapia Celular - TerCel [RD12/0019/0029]
- Red de Investigacion Cardiovascular - RIC [RD12/0042/0047]
- Fondo de Investigacion Sanitaria, Instituto de Salud Carlos III projects as part of the Plan Nacional de I+D+I [FIS PI14/01682]
Dilated cardiomyopathy (DCM) remains the most frequent cause of cardiac transplant and thus results in an enormous cost burden for health care systems worldwide. Although DCM is thought to be induced mainly by genetic and/or environmental factors, the cause is unknown in the majority of cases, giving rise to the term idiopathic DCM. Marked cardiac endothelial changes are associated with disease progression and outcome, and there are ongoing efforts to identify biomarkers that have diagnostic and prognostic value. Here, we discuss the potential and the limitations of circulating endothelial progenitor cells (EPCs) as minimally invasive serological biomarkers for DCM. In this context, it is essential to further evaluate their clinical utility independently of other variable factors that can also affect EPC levels such as age, gender, lifestyles, and treatments. To that end, large multicenter studies and standardized instrument settings, reagents, and sample preparation protocols are needed to confirm this.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据